Trials / Completed
CompletedNCT03297424
A Study of PLX2853 in Advanced Malignancies.
A Phase 1b Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Opna Bio LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.
Conditions
- Small Cell Lung Cancer
- Uveal Melanoma
- Ovarian Clear Cell Carcinoma
- Non-Hodgkin Lymphoma
- Advanced Malignancies
- Solid Tumor
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PLX2853 | tablets |
Timeline
- Start date
- 2017-09-12
- Primary completion
- 2021-06-07
- Completion
- 2021-06-07
- First posted
- 2017-09-29
- Last updated
- 2022-07-25
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03297424. Inclusion in this directory is not an endorsement.